查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867109

导管相关血流感染疾病市场按产品类型、最终用户和涂层划分 - 全球预测 2025-2032

Catheter-related Bloodstream Infections Market by Product Type, End User, Coating - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，导管相关血流感染疾病市场规模将达到 27.9 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 17.4亿美元
预计年份：2025年 18.4亿美元
预测年份 2032 27.9亿美元
复合年增长率 (%) 6.10%

该框架着重于影响导管相关感染预防和医疗设备应用的关键临床问题、相关人员的责任以及相互交织的动态。

导管相关血流感染是贯穿从急诊护理到社区护理等各个阶段的持续性挑战，造成了沉重的临床负担，并推动着医疗设备设计、临床实践和感染预防策略的不断创新。本文从病人安全、不断发展的护理标准以及临床结果与采购和监管决策的交汇点出发，阐述了这个问题的重要性。透过围绕技术、实践和政策展开讨论，相关人员可以更有效地评估哪些干预措施能够带来最大的临床和营运价值。

随着支付方和监管机构日益重视品质指标和与报销挂钩的治疗结果，临床团队面临越来越大的压力，需要减少可预防的感染疾病。同时，医疗设备製造商和医院采购负责人必须平衡临床疗效、成本控制和供应链可靠性。因此，导管相关感染预防领域正在促进临床医生、感染预防专家、供应链管理人员和产业合作伙伴之间加强合作，以推动整合技术、培训和流程优化的多方面解决方案。

本导言为深入的高阶主管分析奠定了基础，重点阐述了影响当今决策的关键驱动因素：医疗设备和涂层的临床疗效、护理标准和综合治疗方案、医护人员的能力和依从性，以及决定产品应用路径的更广泛的经济和监管环境。预先阐明这些主题，使得后续章节能够探讨变革性转变、细分市场动态、区域趋势、供应商策略，并为寻求同时降低感染风险和优化医疗服务的领导者提供切实可行的建议。

医疗设备科学的创新、实证通讯协定和跨部门合作正在汇聚，重新定义感染预防策略和临床应用路径。

重大变革正在重塑医疗系统、临床医生和製造商应对导管相关血流感染的方式。材料科学和表面工程的进步催生了新型的器械级防护技术，而插入技术、维护通讯协定和即时监测的逐步改进正在改变临床工作流程。这些变革共同建构了一个更完善的感染预防体系，超越了单一产品和操作流程，朝着整合式照护模式迈进。

同时，实证医学的作用日益凸显。高品质的比较疗效研究和务实的临床试验正在影响采购决策和临床指南，推动医疗实践从主导转向数据主导。医疗系统越来越关注可衡量的结果，凸显了健全的上市后监测和标准化感染追踪机制部署的重要性。同时，从电子检查清单到导管留置时间的远端监测等数位医疗工具正在试验应用，并在某些情况下得到推广，以帮助确保患者依从性并及早发现併发症。

此外，跨部门合作日益突出。製造商正与临床医生和学术机构合作，共同製定优化医疗设备在实际应用中的通讯协定。支付者也积极参与以价值为导向的对话，优先考虑持续的临床效益。这些变革正在创造一个充满活力的环境，改变感染预防领域的临床实践和采购模式，使渐进式技术进步、严谨的证据和系统层面的奖励汇聚一堂。

评估关税变化对采购、定价和供应商策略的影响如何改变感染预防产品的采购决策和供应链韧性。

美国近期关税调整为导管相关感染预防产品的供应链计算和采购决策引入了新的变数。其累积影响不仅限于简单的价格调整，还延伸至供应商筹资策略、库存管理以及国内製造商与国际供应商之间的竞争。采购团队被迫重新评估供应商多元化、双重采购和库存缓衝，以降低下游短缺和成本波动的风险。

面对不断上涨的原材料成本和可能征收的进口关税，製造商正采取一系列措施，包括将生产转移到近岸地区、与零件供应商重新谈判以及有针对性地调整价格。这些措施正在影响医院的采购行为，促使医院签订更长期的合同，更加关注总体拥有成本 (TCO)，并制定更严格的供应商绩效指标。一些医疗系统正在加快采用已被证实有效的、能够缩短住院时间和减少併发症相关资源消耗的产品，从而抵消额外的采购成本。

监管机构和政策相关人员正透过发布指南来应对，以确保医疗服务的连续性并优先考虑供应链透明度；与此同时，行业相关人员正在探索建立联合采购联盟和框架，以维持采购能力并实现各类医疗机构的平等获取。因此，随着各机构在成本压力和预防可避免的血流感染的临床需求之间寻求平衡，以供应链韧性和价值主导采购为核心的市场正在兴起。

深度分割分析揭示了设备类型、临床环境和涂层技术如何相互作用，从而影响临床选择、采购和实施策略。

细分市场分析揭示了产品类型、最终用户和涂层方法的不同趋势，这些趋势共同决定了产品的采用和创新重点。以产品类型为基础的市场格局可分为中央静脉导管和周边静脉导管。中央静脉导管又可细分为非周边置入中央静脉导管和周边置入中央静脉导管，而周边静脉导管则包括中线导管和标准週边静脉导管。每个子类别都有其独特的临床适应症、使用时间长度和风险特征，这些因素都会影响器材的选择和辅助预防策略。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在加护病房(ICU) 中引入抗菌银合金和抗生素浸渍导管可降低感染率
  • 建立快速分子诊断平台，用于早期检测导管相关血液中的病原体，从而实现标靶治疗。
  • 将人工智慧驱动的预测分析与电子健康记录相结合，以主动识别医院中高风险的导尿患者
  • 开发一种新型抗菌肽涂层，并结合奈米技术，以实现对导管表面持续的保护，防止生物膜形成。
  • 在肿瘤科病房推广使用牛磺罗定和乙醇製剂的抗菌封管疗法通讯协定，以预防中央静脉导管感染。
  • 用于加护病房和急诊室床边血液传播传染病筛检的照护现场微流体设备
  • 引入远端医疗导管部位监测系统，以提高无菌操作技术的依从性并降低感染率
  • 欧盟医疗设备法规 (MDR) 的更严格监管要求要求抗菌导管产品必须提供全面的临床数据才能获得欧洲市场的核准。
  • 医院向抗菌药物管理计划过渡，该计划包括导管感染监测和基于指南的导管更换策略
  • 在以价值为导向的医疗保健环境下评估新型抗菌导管技术的成本效益和报销模式

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的导管相关血流感染疾病市场

  • 中央静脉导管
    • 非周边置入中央静脉导管
    • 周边置入中央静脉导管
  • 週边静脉导管
    • 中线导管
    • 标准週边静脉导管

9. 依最终用户分類的导管相关血流感染疾病市场

  • 门诊手术中心
  • 居家医疗环境
  • 医院

10. 导管相关血流感染疾病市场（依涂层分类）

  • 抗菌涂层
    • 抗生素浸渍
    • 洛赫西定定涂层
    • 银涂层
  • 未涂层

11. 各地区导管相关血流感染疾病市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

12. 导管相关血流感染疾病市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国导管相关血流感染疾病市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Becton, Dickinson and Company
    • B. Braun Melsungen AG
    • 3M Company
    • Teleflex Incorporated
    • ICU Medical, Inc.
    • Johnson & Johnson
    • Molnlycke Health Care AB
    • Cook Medical LLC
    • AngioDynamics, Inc.
    • Baxter International Inc.
Product Code: MRR-5D693B46C67B

The Catheter-related Bloodstream Infections Market is projected to grow by USD 2.79 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.74 billion
Estimated Year [2025] USD 1.84 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 6.10%

A focused framing of clinical imperatives, stakeholder responsibilities, and the converging forces that shape catheter-related infection prevention and device adoption

Catheter-related bloodstream infections remain a persistent challenge across acute and community care environments, producing significant clinical burden and driving continuous innovation in device design, clinical practice, and infection prevention strategies. This introduction frames the issue in terms of patient safety imperatives, evolving standards of care, and the intersection of clinical outcomes with procurement and regulatory decision-making. By situating the discussion around technology, practice, and policy, stakeholders can more effectively assess where interventions will yield the greatest clinical and operational value.

Clinical teams face increasing pressure to reduce preventable infections as payers and regulators emphasize quality metrics and reimbursement-linked outcomes. At the same time, device manufacturers and hospital procurement leaders must balance clinical performance with cost containment and supply chain reliability. As a result, the landscape for catheter-related infection prevention is characterized by intensified collaboration between clinicians, infection preventionists, supply chain managers, and industry partners, fostering multidisciplinary solutions that integrate technology, training, and process optimization.

This introduction sets the stage for a detailed executive-level analysis by highlighting the key drivers that shape decision-making today: clinical efficacy of devices and coatings, procedural standards and bundles, workforce competency and adherence, and the broader economic and regulatory context that determines adoption pathways. By clarifying these themes up front, the subsequent sections can explore transformational shifts, segmentation dynamics, regional patterns, vendor strategies, and practical recommendations for leaders seeking to reduce infection risk while optimizing care delivery.

How innovations in device science, evidence-based protocols, and cross-sector collaboration are converging to redefine infection prevention strategies and clinical adoption pathways

Significant transformative shifts are reshaping how healthcare systems, clinicians, and manufacturers approach catheter-related bloodstream infections. Advances in material science and surface engineering are translating into new device-level protections, while incremental improvements in insertion technique, maintenance protocols, and real-time monitoring are altering clinical workflows. Together, these changes are creating a more layered defense against infection that extends beyond a single product or practice and toward integrated bundles of care.

Simultaneously, the role of evidence generation has intensified; high-quality comparative effectiveness research and pragmatic trials are influencing purchasing decisions and clinical guidelines, driving a movement from anecdote-driven adoption to data-driven implementation. Health systems are increasingly focused on measurable outcomes, which has elevated the importance of robust post-market surveillance and adoption of standardized infection tracking mechanisms. In parallel, digital health tools-ranging from electronic checklists to remote monitoring of catheter dwell times-are being piloted and, in some cases, scaled to support adherence and early detection of complications.

Moreover, cross-sector collaboration is becoming more prominent: manufacturers are partnering with clinicians and academic centers to co-develop protocols that optimize device use in real-world settings, and payers are engaging in value-based conversations that prioritize durable clinical benefit. Taken together, these transformative shifts are producing a dynamic environment where incremental technical advances, rigorous evidence, and system-level incentives coalesce to change both practice and procurement in infection prevention.

Assessing how tariff-driven shifts in sourcing, pricing, and supplier strategy are reshaping procurement decisions and supply chain resilience for infection prevention products

Recent tariff changes in the United States have introduced a new variable into supply chain calculus and procurement decision-making for catheter-related infection prevention products. The cumulative impact extends beyond simple price adjustments and touches vendor sourcing strategies, inventory management, and the competitive dynamics between domestic manufacturers and foreign suppliers. Procurement teams have been required to reassess supplier diversity, dual sourcing, and inventory buffers to mitigate the risk of downstream shortages or cost volatility.

Manufacturers facing higher input costs and potential import levies have responded with a mix of nearshoring, renegotiation with component vendors, and targeted price realignments. These responses, in turn, influence hospital purchasing behavior, encouraging longer-term contracting, increased emphasis on total cost of ownership, and more rigorous supplier performance metrics. In some cases, health systems are accelerating adoption of products with proven efficacy that can reduce length of stay or complication-related resource use, thereby offsetting incremental acquisition costs.

Regulatory and policy stakeholders have also adapted by issuing guidance to ensure continuity of care and to prioritize supply chain transparency. Meanwhile, industry participants are exploring collaborative procurement consortia and pooled purchasing arrangements to preserve purchasing leverage and normalize access across different facility types. The net effect is a market that is more attuned to supply chain resilience and value-driven procurement, with organizations balancing cost pressures against the clinical imperative to prevent avoidable bloodstream infections.

Deep segmentation insights revealing how device type, care setting, and coating technologies intersect to shape clinical selection, procurement, and implementation strategies

Segment-level analysis reveals distinct dynamics across product type, end user, and coating modality that collectively inform adoption and innovation priorities. Based on product type, the landscape differentiates between central venous catheters and peripheral venous catheters, with central venous catheters further divided into non-peripherally inserted central catheters and peripherally inserted central catheters, while peripheral venous catheters encompass midline catheters and standard peripheral intravenous catheters; each subcategory presents unique clinical indications, dwell time considerations, and risk profiles that influence device selection and adjunctive prevention strategies.

Based on end user, utilization and purchasing pathways vary across ambulatory surgical centers, home care settings, and hospitals, with each setting imposing distinct logistic, staffing, and training constraints. Hospitals typically centralize infection control expertise and have established procurement infrastructures, whereas ambulatory surgical centers and home care settings may prioritize devices that are simple to use, require minimal maintenance, and support rapid patient turnover or remote management.

Based on coating, differentiation between antimicrobial coated and non-coated devices is a critical axis. The antimicrobial coated segment is further characterized by antibiotic-impregnated, chlorhexidine coated, and silver coated options, each offering different spectra of antimicrobial activity, longevity, and regulatory considerations. These coating choices interact with clinical protocols and stewardship priorities, influencing clinician preference, formulary decisions, and post-market surveillance requirements. Understanding how these segmentation dimensions intersect is essential for stakeholders aiming to optimize clinical outcomes while aligning with operational needs and stewardship goals.

How regional regulatory frameworks, manufacturing footprints, and clinical practice variability across key geographies drive differentiated strategies for device adoption and distribution

Regional dynamics influence clinical practice, regulatory emphasis, and supply chain architecture in ways that matter to stakeholders operating across Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, policy emphasis on quality metrics and reimbursement-linked outcomes has pushed institutions to prioritize interventions with demonstrable reductions in infection risk, while robust domestic manufacturing capacity has supported supply chain continuity in many areas. In contrast, Europe, Middle East & Africa present a more heterogeneous environment where regulatory frameworks, health infrastructure maturity, and procurement models vary significantly, driving the need for region-specific strategies and localized evidence to support product adoption.

Asia-Pacific is characterized by rapid infrastructure expansion, growing clinical capacity in both acute and community care, and an increasing focus on infection prevention as standards evolve. Supply chain dynamics across these regions differ as well, with Asia-Pacific often serving as a key manufacturing hub and the Americas and Europe representing large, sophisticated demand centers. These regional contrasts create opportunities for tailored go-to-market approaches that account for regulatory pathways, local clinical practice patterns, and distribution network realities.

Consequently, companies and health systems should calibrate their regional engagement strategies to reflect differences in evidence requirements, procurement cycles, and implementation capacity. Regional partnerships, targeted clinical data generation, and adaptive distribution models are typically most effective when they align with the specific operational and regulatory contours of each geography.

Competitive and collaborative strategies among manufacturers and service providers that prioritize evidence generation, integrated solutions, and supply chain resilience to gain clinical trust

Competitive activity among device manufacturers, coating technology providers, and services organizations is shaping both product development and market engagement strategies. Leading players are investing in next-generation materials and coating chemistries that improve antimicrobial performance while minimizing impact on antimicrobial stewardship initiatives. At the same time, portfolio diversification is evident as manufacturers seek to offer bundled solutions that combine devices, training, and digital adherence tools to strengthen clinical outcomes and customer retention.

Strategic partnerships between industry and clinical centers of excellence are increasingly common, facilitating real-world evidence generation and supporting guideline inclusion. Meanwhile, contract manufacturers and logistics providers are evolving their service offerings to address resilience concerns by providing dual-sourcing options, localized inventory hubs, and enhanced traceability. Mergers and acquisitions activity continues to reflect a desire to integrate novel coating technologies and point-of-care monitoring capabilities into broader product suites, enabling companies to offer differentiated value propositions to hospitals and alternative care sites.

Innovation in post-market surveillance and data analytics is also influencing competitive positioning, as companies that can demonstrate longitudinal safety and efficacy data gain traction with procurement committees and clinical leaders. Overall, the competitive landscape prizes agility in R&D, capacity to generate strong clinical evidence, and the ability to deliver comprehensive solutions that reduce infection risk across diverse care settings.

Practical, evidence-driven actions for manufacturers and health systems to enhance clinical outcomes, secure supply chain continuity, and accelerate safe adoption of infection prevention innovations

Industry leaders should adopt a pragmatic, multi-dimensional strategy to reduce catheter-related bloodstream infections that balances innovation, implementation, and system-level change. First, prioritize investment in clinical evidence that demonstrates not just product performance but real-world impact on infection rates and resource utilization. Complement device innovation with prospective observational studies and partnerships with health systems to capture meaningful outcomes and implementation insights.

Second, strengthen supply chain resilience through supplier diversification, contingency inventory strategies, and collaborative procurement models. Near-term tariff and trade uncertainties underscore the value of local manufacturing options and flexible sourcing arrangements, which can reduce exposure to single-source disruptions and support steady access to critical components and finished devices.

Third, integrate product adoption with workforce training and process redesign. Devices with advanced coatings or novel designs should be introduced alongside comprehensive competency programs, standardized insertion and maintenance bundles, and digital tools that support adherence and monitoring. Embedding change management and clear accountability in clinical pathways increases the likelihood that technical benefits translate into measurable reductions in infection risk.

Finally, engage proactively with regulators and payers to align on evidence requirements and reimbursement models that recognize the longer-term value of infection prevention. By taking a holistic approach that combines robust evidence, operational readiness, and adaptive procurement, leaders can accelerate safe adoption while managing cost and compliance pressures.

A transparent mixed-methods approach combining clinician interviews, guideline review, and triangulated evidence synthesis to produce rigorous and actionable insights

The research methodology underpinning this analysis leverages a blend of primary and secondary approaches to ensure rigor, triangulation, and relevance to stakeholders. Primary research comprised structured interviews with clinicians, infection prevention specialists, procurement leaders, and industry executives to capture first-hand perspectives on device performance, adoption barriers, and operational priorities. These interviews were complemented by targeted consultations with regulatory experts and supply chain managers to understand policy implications and logistics considerations.

Secondary research involved systematic review of peer-reviewed literature, clinical guidelines, and regulatory documents to contextualize primary findings within the broader evidence landscape. Where available, post-market surveillance reports, real-world evidence studies, and technical white papers were reviewed to assess safety and performance claims. Data synthesis prioritized cross-validation across sources to reconcile discrepancies and highlight consensus areas versus topics requiring further investigation.

Analytical techniques included qualitative thematic analysis to extract recurrent themes and drivers, as well as comparative assessment frameworks to evaluate relative strengths and limitations across device types, coatings, and care settings. Limitations of the methodology are acknowledged, including variability in published data granularity across regions and rapid innovation cycles that may alter the evidence base over short horizons. To mitigate these constraints, the study incorporated stakeholder validation and iterative review cycles to ensure findings remain robust and actionable.

A strategic synthesis underscoring the imperative of combining innovation, evidence, and operational rigor to consistently reduce infection risk and improve patient safety

In conclusion, addressing catheter-related bloodstream infections requires an integrated strategy that aligns device innovation, clinical practice improvement, and supply chain robustness. Technical advances in catheter design and antimicrobial coatings are important, but their full value is realized only when paired with rigorous evidence generation, comprehensive training, and operational systems that support adherence. As stakeholders navigate tariff-driven disruptions and regional variability, a focus on resilience, targeted data, and collaborative implementation will distinguish effective programs from those that fall short.

Leaders should therefore pursue coordinated investments: prioritize evidence that demonstrates clinical and operational benefit, build procurement strategies that minimize disruption risk, and embed change management into clinical rollouts. By doing so, health systems can protect patient safety while preserving financial sustainability, and manufacturers can create durable partnerships with customers grounded in measurable outcomes. The path forward emphasizes iterative learning, cross-sector collaboration, and a sustained commitment to translating technical promise into consistent, real-world reductions in infection risk.

These conclusions offer a strategic foundation for stakeholders ready to move from analysis to action, and the recommendations herein are intended to inform both near-term tactical decisions and longer-range strategic planning in the pursuit of safer vascular access care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of antimicrobial silver alloy and antibiotic-impregnated catheters in ICU settings to reduce infection rates
  • 5.2. Implementation of rapid molecular diagnostic platforms for early detection of catheter-associated bloodstream pathogens to enable targeted therapy
  • 5.3. Integration of AI-driven predictive analytics with electronic health records for preemptive identification of high-risk catheter patients in hospitals
  • 5.4. Development of novel antimicrobial peptide coatings combined with nanotechnology for long-lasting catheter surface protection against biofilm formation
  • 5.5. Expansion of antimicrobial lock therapy protocols using taurolidine and ethanol formulations to prevent central line infections in oncology wards
  • 5.6. Emergence of point-of-care microfluidic devices for bedside bloodstream infection screening in intensive care units and emergency departments
  • 5.7. Adoption of telehealth-enabled catheter site monitoring systems to improve compliance with aseptic techniques and reduce infection rates
  • 5.8. Stricter regulatory mandates under EU MDR requiring comprehensive clinical data for antimicrobial catheter product approvals in European markets
  • 5.9. Shift towards antibiotic stewardship programs incorporating catheter infection surveillance and guideline-based catheter replacement strategies in hospitals
  • 5.10. Evaluation of cost-effectiveness and reimbursement models for novel antimicrobial catheter technologies in value-based healthcare environments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-related Bloodstream Infections Market, by Product Type

  • 8.1. Central Venous Catheters
    • 8.1.1. Non-Peripherally Inserted Central Catheters
    • 8.1.2. Peripherally Inserted Central Catheters
  • 8.2. Peripheral Venous Catheters
    • 8.2.1. Midline Catheters
    • 8.2.2. Standard Peripheral Intravenous Catheters

9. Catheter-related Bloodstream Infections Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Home Care Settings
  • 9.3. Hospitals

10. Catheter-related Bloodstream Infections Market, by Coating

  • 10.1. Antimicrobial Coated
    • 10.1.1. Antibiotic Impregnated
    • 10.1.2. Chlorhexidine Coated
    • 10.1.3. Silver Coated
  • 10.2. Non-Coated

11. Catheter-related Bloodstream Infections Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Catheter-related Bloodstream Infections Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Catheter-related Bloodstream Infections Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Becton, Dickinson and Company
    • 14.3.2. B. Braun Melsungen AG
    • 14.3.3. 3M Company
    • 14.3.4. Teleflex Incorporated
    • 14.3.5. ICU Medical, Inc.
    • 14.3.6. Johnson & Johnson
    • 14.3.7. Molnlycke Health Care AB
    • 14.3.8. Cook Medical LLC
    • 14.3.9. AngioDynamics, Inc.
    • 14.3.10. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 231. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 236. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 237. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 238. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 239. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 242. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 243. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 244. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS CATHETER-RELA